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Abstract A recombinant polypeptide composed of the a-hefical 
neck region and carbohydrate recognition domain (CRD) of bo- 
vine conglutinin was expressed in Escherichia coli. The recombi- 
nant protein formed inclusion bodies but could be solubilised using 
a denaturation-renaturation cycle based on urea and then purified 
by affinity chromatography on a TSK-N-acetylgincosamine col- 
umn. The purified product behaved as a homotrimer in non- 
dissociating conditions, with three CRDs held together by the 
a-helical neck regions. The trimer, although lacking the N-termi- 
nal and collagen regions of the native conglutinin, showed the 
same binding carbohydrate specificities as the native molecule, 
for the complement fragment C3b and for lipopolysaccharides 
derived from Gram-negative bacteria. 
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1. Introduction 
The collectins are members of a group of oligomeric mam- 
malian lectins composed of polypeptides with N-terminal colla- 
gen-like regions attached via a-helical neck regions to C-termi- 
nal, C-type, lectin domains. The collectins include the serum 
proteins, mannose-binding protein (MBP), bovine conglutinin 
(BK), collectin-43 (CL-43) and the lung surfactant proteins 
SP-A and SP-D [1]. Conglutinin, which was first described as 
a factor which agglutinates complement-reacted erythrocytes 
[2] and has only been fully characterised from bovine serum [3]. 
Conglutinin is composed of 12 identical chains of 44 kDa, each 
chain contains 351 amino acid residues and consists of a short 
N-terminal cysteine-containing re ion of 25 residues followed 
by a 171-residue-long collagenous region and then a short (28 
residues) s-helical neck region which is connected to the, C- 
terminal, globular carbohydrate r cognition domain (CRD) [4]. 
Alignment of the amino acid sequences of bovine conglutinin 
and bovine SP-D shows 78% identity between the two proteins 
[5,6], despite their quite different carbohydrate specificities. As 
judged from electron microscopy and protein chemistry studies, 
conglutinin is composed of four subunits radiating from a cen- 
tral hub. Each subunit being composed of a triple-helical, colla- 
gen-like, rod connected by an a-helical 'neck' region to three, 
C-terminal, C-type lectin domains [7]. 
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Bovine conglutinin is able to mediate the agglutination of 
serum-reacted erythrocytes. The ligand recognised by con- 
glutinin in this reaction has been shown to be iC3b derived from 
C3b deposited on the cells. The specific site on iC3b to which 
conglutinin binds is an exposed carbohydrate structure on the 
a'-chain of iC3b [8]. By use of carbohydrate ligands as inhib- 
itors of agglutination of serum-reacted rythrocytes, it can be 
shown that conglutinin binds preferentially to terminal N-ace- 
tylglucosamine [9]. Conglutinin can also cause opsonisation by 
binding to iC3b on the surface of microorganisms [10] and It 
has been shown to bind, via its collagenous region, to the widely 
distributed Clq receptor on phagocytes and other cells [11]. 
In the present study, a polypeptide composed of the neck 
region plus the CRD of bovine conglutinin has been expressed 
in Escherichia coli. This polypeptide, which lacked both the 
N-terminal and collagenous regions of conglutinin, was found 
to form a homotrimer composed of the neck region and CRD 
domains of the protein. The trimeric recombinant material 
showed the same, calcium-dependent, sugar-binding specificity 
as the native protein and also the same affinity for lipopolysac- 
charides (LPS) from Gram-negative bacteria. Also, like native 
conglutinin, the recombinant material bound to C3b in a cal- 
cium- and saccharide-dependent fashion. These results are con- 
sistent with the previous hypothesis that the neck region in each 
of the collectins is essential for trimerisation of the three col- 
lagenous polypeptide chains and in maintenance of multi- 
valency of the binding to microorganisms [12-14]. 
2. Materials and methods 
2.1. DNA construct encoding the neck plus CRD domain of bovine 
conglutinin (recombinant BK-neck-CRD) 
A cDNA clone for conglutinin, previously isolated from bovine liver 
Agtl I cDNA library (Cambridge Biosciences, Cambridge, UK) [3], was 
subcloned in Bluescript-plasmid and used as a template for polymerase 
chain reaction (1/A/100/zl PCR). The two terminal primers, 5'-ATT- 
AGGATCCGCAGAGGTCAATGCTCTCA-3' (forward primer) and 
5'-TGCTAGTTATTGCTCAGCGG-Y (T7 primer) were used to am- 
plify a cassette which encoded for the neck plus lectin domain of bovine 
conglutinin. The PCR product was cleaved with BamH1 and EcoR1 
and ligated to the BamH1-EcoRI cleaved backbone of a modified pET 
vector [15] and transformed into competent E. coli DH5~ cells. The 
resultant recombinant plasmid, pBK was introduced into the expres- 
sion host of E. coli BL21 (2DE3) which carries the chromosomally 
integrated T7 RNA polymerase gene under the control of the lac UV5 
promoter 
2.2. Expression and purification of the recombinant eck region plus 
lectin domain of bovine conglutinin ( BK-neck-CRD) 
F~ coli BL21 (2DE3), containing plasmid pBK, was grown to an OD 
of 0.8 at 700 nm in 1 1 LB medium in the presence of ampicillin (100 
/zg/ml) at 37°C, with vigorous aeration. IPTG (isopropyl-13-o-thiogalac- 
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topyranoside, NOVA Biochem) was added to a final concentration f
0.,z mM to induce the T7 RNA polymerase gene in the host chromo- 
some. The cells were shaken under these conditions for 3 h and har- 
vested. The wet cell pellet was suspended in ice-cold lysis buffer [20 mM 
Tris-HCI]500 mM NaC1, pH 8.0, containing 0.25% (v/v) Tween 20, 
2 ~nM EDTA, 2 mM EGTA, 1 mM phenylmethylsulfonyl fluoride 
(PVISF; Sigma, Poole, UK) and 200/2g/ml of lysozyme (Sigma) for 30 
mm and the lysate was then sonicated at 60 Hz for 2 min with an 
interval of 1 min (15 cycles) to shear the chromosomal DNA. After 
so:lication and centrifugation at 16,000 rpm for 30 min, most of the 
ex ~ressed recombinant protein was present in the pellet. Therefore. a
de laturing and refolding procedure was carried out on the cell pellet 
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Fig. 2. Elution profile of recombinant bovine conglutinin from an 
FPLC Superose 12 column (HR 10/30). Approximately 0.14).2 mg (in 
0.2 ml) of recombinant material was applied to the column. The column 
was eluted with TBS-NTC buffer (solid line) or TBS-EDTA buffer 
(dotted line), at a flow rate of 0.2 ml/min. The absorbance at 280 nm 
was measured and 0.5-ml fractions were collected and examined by 
SDS-PAGE. Calibration of the column was carried out using the fol- 
lowing marker proteins: alchohol dehydrogenase (150 kDa), bovine 
serum albumin (67 kDa), soybean trypsin inhibitor (20.3 kDa), cycto- 
chrome c(12.4 kDa). The elution positions of molecular weight markers 
are shown above the elution profiles. 
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Fi~. 1. (a) SDS-PAGE analysis in different steps of purification of the 
recombinant bovine conglutinin. Lane 1 contains molecular weight 
standards. From top to bottom are 97.4 kDa, 66.2 kDa, 45.0 kDa, 31.0 
kDa, 21.5 kDa and 14.4 kDa. Lanes 2 to 7 show various steps in the 
purification: lane 2, total cell lysate without IPTG induction; lane 3, 
tolal cell lysate after IPTG induction; lane 4, insoluble fraction after 
ce~ trifugation of the IPTG-induced and sonicated cell lysate; lane 5, 
fin,tl soluble fraction of cell lysate after denaturation a d then refolding 
by dialysis against decreasing concentrations of urea; lane 6, the major 
pet~.k eluted, with the NaCI gradient, from the DEAE-cellulose column; 
lane 7, recombinant protein eluted from the TSK-GluNac column by 
TBS-NTC buffer containing 10 mM N-acetylglucosamine; lane 8, re- 
co~abinant protein eluted from TSK-GluNac column by TBS buffer 
cor~taining 10 mM EDTA. All the samples were run on 15% (w/v) 
SDS-PAGE under educing conditions. (b) Immunoblotting of recom- 
binant BK-neck-CRD. Lane 1, the total cell lysate (10/2g/ml) after 
induction with IPTG; lane 2, recombinant protein eluted from the 
TSK-GIuNac column by TBS-NTC buffer containing 10 mM N-ace- 
tylglucosamine; lane 3, recombinant protein eluted from the TSK- 
GhtNac column by TBS buffer containing 10 mM EDTA. Samples 
were transferred onto a Hybond-C membrane. The blot was probed 
using a biotinylated rabbit anticonglutinin IgG (h1000 dilution)/strep- 
ta~.idin alkaline phosphatase d tection system. 
(starting at 6 M and reducing to zero). The starting buffer, containing 
20 mM Tris-HCl/100 mM NaCl, pH 8.0, 5% (v/v) glycerol and 6 M 
urea, was used to resuspend the cell pellet and repetitive dialysis per- 
formed against 1000 vols. of the same buffer containing decreasing 
concentrations of urea. The final supernatant containing soluble recom- 
binant BK-neck-CRD protein was dialysed against ion-exchange start- 
ing buffer (20 mM Tris-HC1/50 mM NaC1, pH 7.4) and loaded to 
DEAE column (20 ml) and eluted on a Pharmacia HighLoad FPLC 
(Pharmacia, Milton Keynes, UK). The recombinant BK-neck-CRD 
was eluted by Tris buffer containing 250 mM NaCI. The eluant was 
pooled and dialysed against hree changes of TBS-NTC buffer (50 mM 
Tris-HCl/150 mM NaC1, 0.05% (w/v) NAN3, 0.05% (v/v) Tween 20 and 
5 mM CaClz, pH 7.4). The dialysate was applied to a TSK-N-acetylglu- 
cosamnie (TSK-GIuNac) column. After washing with 5 bed volumes of 
TBS-NTC, bound protein was eluted with TBS-NTC buffer containing 
10 mM GluNac. The purity and identity of the recombinant BK-neck- 
CRD was assessed by 15% (w/v) SDS-PAGE and detected by Western 
blotting, using rabbit antibovine conglutinin IgG (gift from Dr. U. 
Holmoskov, University of Odense, Denmark). 
2.3. Characterisation of the recombinant BK-neck-CRD 
The gel-filtration chromatography was performed on a FPLC system 
(Pharmacia, Milton Keynes, UK) using a Superose 12 HR 10/30 (Phar- 
macia Biotech, Sweden) column. Approximately 0.1-0.2 mg (in 0.2 ml) 
of recombinant protein was applied to the column. For each applica- 
tion, the column was eluted with 20 mM Tris-HCl/100 mM NaC1, pH 
7.4, containing 5 mM CaC12 or 10 mM EDTA, at flow rate of 0.5 
ml/min. 
2.4. Saccharide-binding specificities of recombinant BK-neck-CRD 
The relative potencies of a number of monosaccharides and disaccha- 
rides at inhibiting the binding of biotinylated recombinant BK-neck- 
CRD to mannan were estimated. Recombinant BK-neck-CRD (200/2g 
in 2 ml 0.1 M NaHCO3 buffer, pH 8.0) was biotinylated by incubation 
with biotinyl-N-hydroxy succinimide ster (BNHS; l0/21 of a 5 mg/ml 
solution (Sigma)) for 3 h at room temperature. The biotinylated protein 
was dialysed 3 × against TBS buffer (pH 7.4) to remove unbound 
labelling reagents. The sugar-binding characteristics were tested in a 
solid-phase carbohydrate assay as previously described [12]. In this 
assay, dilutions of recombinant BK-neck-CRD were incubated alone, 
or with dilutions of different saccharides, on mannan-coated plates. 
The bound recombinant BK-neck-CRD was detected immunochemi- 
cally. 
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2.5. Binding of the recombinant BK-neck-CRD to C3b and to LPS 
Complement component C3 was purified from normal human serum 
as described elsewhere [16] and was digested with 1% (w/w) trypsin 
(Sigma; type T2271) for 90 s at 37°C in order to generate C3b [8]. The 
analysis of binding of recombinant BK-neck-CRD to fluid-phase C3b 
was carried out as described by Laursen et al. [17], Briefly, purified 
recombinant BK-neck-CRD (1/Jg/well) was coated on microtitre plates 
and, after incubation and washing, the plates were incubated with 
various concentrations of purified C3b in either TBS-NTC alone, TBS- 
NTC containing 100 mM GluNac, or TBS-NTE (50 mM Tris-HCl/150 
mM NaC1, 0.05% (w/v) NAN3, 0.05% (v/v) Tween-20 and 10 mM 
EDTA, pH 7.4). After 2 h of incubation at 4°C, the plates were washed 
and biotinylated rabbit anti-C3b antibody in 0.1/Jg in 100pl was added. 
After incubation for 2 h, the microtitre wells were developed using an 
extravidin-alkaline phosphatase-alkaline phosphatase substrate sys- 
tem. 
The binding of LPS to native and recombinant BK-neck-CRD was 
measured by sandwich ELISA methods as previously described [12]. 
Lipopolysaccharides from E. coli (L8274), Klebsiella pneumoniae 
(L4268) and Pseudomonas eruginosa (L9143) were all purchased from 
Sigma. TBS buffers containing 5 mM CaC12, or 10 mM EDTA, or 5 
mM CaCI: plus 100 mM of saccharide (mannose or GluNac), were used 
to determine if the binding to LPS was calcium-dependent a d lectin- 
specific. 
3. Results and discussion 
3.1. Bacterial expression of a fragment of human bovine 
conglutinin: BK-neck-CRD 
The expressed recombinant fragment of conglutinin, con- 
tains residues 197 351 of the mature protein, corresponding to
28 amino acids of the s-helical neck region (residues 197-224) 
and the 127-amino-acid-long, C-terminal, CRD (residues 225- 
351). Most of the expressed protein formed inclusion bodies 
was recovered from the cell pellet (Fig. l a, lane 4). The insolu- 
ble recombinant material was denatured and gradually refolded 
[18] by dialysis against decreasing concentrations of urea-TBS 
buffer (Fig. la, lane 5). The BK-neck-CRD was purified by ion 
exchange and affinity chromatography and gave a major band 
of 23 kDa on reducing, and non-reducing, conditions on SDS- 
PAGE (Fig. la, lane 8). The identity of the recombinant protein 
was confirmed by immunoblotting, using rabbit antibovine 
conglutinin IgG as a probe (Fig. lb, lanes 2 and 3). 
These results show that recombinant BK-neck-CRD can be 
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Fig. 4. (a) The binding of C3b to the recombinant BK-neck-CRD- 
coated microtitre plates in the presence of various inhibitors. Details 
are given in section 2. Binding was carried out in buffers containing: 
5 mM CaCI2 (e); 50 mM mannose (u); 50 mM GluNac (*); 10 pg/ml 
native conglutinin (*). (b) Sugar inhibition of C3b binding to recombi- 
nant BK-neck-CRD. Details are given in section 2. Binding was carried 
out in the presence of EDTA (*); Mannose (-,); GluNac (*). 
the purified recombinant protein refolds correctly, as judged by 
its retention on a TSK-GluNac lectin-affinity column. 
3.2. Characterisation of recombinant BK-neek-CRD 
The molecular size of the recombinant BK-neck-CRD, in 
non-dissociating conditions, was determined by gel filtration on 
Sepharose 12 chromatography at room temperature in the pres- 
ence of TBS buffer containing EDTA (10 mM), or CaCI 2 (5 
mM). In Fig. 2, it can be seen that the 155-residue-long peptide 
of the expressed fragment, BK-neck-CRD, behaved as a single 
peak having apparent molecular weight of approximately 64 
kDa. This retention profile was not significantly changed when 
the eluting buffer contained EDTA (10 mM) (dotted line) in- 
stead of calcium ions (solid line). The peak fractions were col- 
lected and shown to give a major band of 23 kDa when exam- 
ined by SDS-PAGE, under reducing and non-reducing condi- 
tions. Thus, residues 197-351 of conglutinin are sufficient o 
form a homotrimer of the 23-kDa recombinant peptide in non- 
dissociating conditions and this trimerisation of the recombi- 
nant BK-neck-CRD is not affected by Ca 2+ or EDTA. Al- 
though we have not expressed the CRD domain of BK on its 
own, the studies by Hoppe et al. [13] on the c~-helical neck 
region and unpublished work in this laboratory on the recom- 
binant fragments of human SP-D (neck region with CRD do- 
main and CRD domain alone) have shown that the neck region 
of human SP-D is essential for the trimerisation and orientation 
of the CRDs of human SP-D. Also the crystal structures of the 
neck region plus CRDs of human and rat, MBP are consistent 
with this structural role of the neck region being common to 
all three of these collectins [19-21]. 
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F~ ;. 5 (a) Dose-dependent binding of native conglutinin and BK-neck- 
C~(D to LPS from E. coli (D,I), P aeruginosa (©,#) and 
K pneumonia (~,A). Details given in section 2. (b) Inhibition of the 
billding of recombinant BK-neck-CRD to LPS (E. coli). 100 ktl of 
re,:ombinant BK-neck-CRD (10/lg/ml) were co-incubated with various 
c¢~acentrations f inhibitors in LPS (E. eoli)-coated microtitre wells: 
bluffer containing CaC12 (o), buffer containing EDTA (B), buffer con- 
taming mannose (A) and buffer containing native conglutinin (#). The 
b~,und recombinant BK-neck-CRD protein was detected with biotinyl- 
at~d rabbit antibovine conglutinin IgG followed by alkaline phosphat- 
as,',-avidin and the substrate for alkaline phosphatase. Colour develop- 
mnt  was measured by reading the OD at 405 nm. 
3. ~. Sugar specificities of the recombinant BK-neck-CRD 
To examine the sugar-binding specificity of the recombinant 
B~:,-neck-CRD protein, a sugar inhibition assay was carried 
o~ t. Recombinant BK-neck-CRD bound, in a calcium-depend- 
e]t manner, as strongly as natural conglutinin to mannan- 
c(ated plates (Fig. 3), whereas neither protein showed any 
si<nificant binding to maltosyl-BSA-coated plates (data not 
sl ~ 3wn). The use of a variety of monosaccharides and disaccha- 
ri~tes as inhibitors of the binding of recombinant BK to man- 
nt, n-coated microtitre plates indicated that recombinant BK- 
ntck-CRD has a similar carbohydrate-binding specificity to 
th ~t of native conglutinin (Table 1), which suggests that the 
C?,D in the recombinant BK-neck-CRD was correctly folded. 
3. t. The binding of recombinant BK-neck-CRD to C3b 
Hirani et al. [8] reported that the conglutinin-binding site on 
th~ third component of human complement is the carbohydrate 
m,)iety located on the N-terminal 27-kDa polypeptide of the 
cg-chain. The mechanism of conglutination and the high affin- 
ity shown by conglutinin for iC3b bound to cell surfaces or to 
iC3b-coated immune complexes is not fully understood and it 
has been suggested that protein-protein interaction, rather than 
protein-carbohydrate interaction, between conglutinin and C3b 
may play a role [22]. The ELISA procedures used here showed 
that the binding of fluid-phase C3b to immobilised recombi- 
nant BK-neck-CRD was dose- and calcium-dependent a d that 
this binding was inhibited by GluNac, mannose and also by 
native, full-length, bovine conglutinin (Fig. 4a). To determine 
the inhibitory capacity of GluNac and mannose, the binding of 
a constant amount of C3b to recombinant BK-neck-CRD in 
the presence of various concentrations of the sugars was tested 
(Fig. 4b). Approximately 70% inhibition was achieved with 20 
mM GluNac and 55% inhibition was observed with 20 mM 
mannose. Thus, these results are in agreement with the view 
that the binding site for conglutinin on the C3 molecule is the 
carbohydrate moiety on the ~'-chain of C3 and that this inter- 
action requires calcium and can be inhibited by N-acetylglu- 
cosamine and to a lesser degree by mannose. The finding that 
purified fluid-phase C3b bound to the recombinant BK is con- 
sistent with the results by Hirani et al. [8] and Laursen et al. [17] 
who found that purified C3, C3b, iC3b and C3c all were bound 
by native conglutinin i  a similar type of ELISA to the one used 
in this study. If C3, or C3 split products, are used in the form 
of whole serum, or activated whole serum, then only iC3b was 
found to bind to natural conglutinin coated onto ELISA plates 
[17]. This indicates that the binding of purified C3, C3b or C3c 
to conglutinin may be due to some conformational change 
taking place, during the purification procedures employed, 
which allows exposure of the carbohydrate arget, on the C3cg- 
chain, which is recognised by conglutinin [17]. 
3.5. LPS-binding assays 
The abilities of the recombinant BK-neck-CRD or native 
conglutinin to bind LPS from Gram-negative bacteria were 
tested by ELISA. As seen in Fig. 5a, both native conglutinin 
Table 1 
Sugar specificities of the BK-neck-CRD recombinant material and na- 
tive conglutinin 
Sugar inhibitors Recombinant Native conglutinin [25] 
BK-neck-CRD 
(this study) 
Maltose 38 (1.73) > 50 
Glucose 15 (0.68) 16 (0.8) 
ManNAc 29 (1.32) 23 (1.2) 
Mann 6 (0.28) 7 (0.35) 
GIuN 27 (1.23) 15 (0.75) 
D-fucose N.D. 31 (1.55) 
GalN > 50 20 (1.0) 
Mannose 22 (1.0) 20 (1.0) 
Galactose > 50 > 50 
L-fucose 32 (1.45) 15 (0.8) 
GIuNAc 7 (0.32) 0.75 (0.04) 
GalNAc > 50 > 50 
Lactose N.D. > 50 
The values given are IC50 (mM), i.e. the concentration required for 50% 
inhibition of binding of biotinylated lectin to mannan. The values in 
parentheses denote IC50 concentration relative to mannose. GAIN, (N- 
galactosamine); GalNAc, (N-acetyl-D-galactosamine); GIuN, (N-glu- 
cosamine); GluNAc, (N-acetyl-D-glucosamine); ManN, (N-Manno- 
samine); ManNAc, (N-acetyl-D-monosamine). N.D. (not performed). 
Conditions for the assay are described in section 2. 
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and recombinant BK-neck-CRD were able to bind to the 
lipopolysaccharides from K. pneumonia, P. aeruginosa and 
E. coli in a similar manner. Moreover, the binding was inhibited 
by 100 mM of mannose, or by 10 mM EDTA, indicating that 
the binding was mediated through typical C-type lectin activity 
(Fig. 5a,b). 
Conglutinin has been shown in vitro to have antibacterial 
activity against Salmonella typhimurium and E. coli, with the 
activity requiring the presence of an intact complement system 
and macrophages [10]. Conglutinin and MBP also appear likely 
to be the fl-inhibitors present in bovine serum that have been 
reported to inhibit the infectivity and hemagglutinating activity 
of different influenza viruses [23]. Moreover, conglutinin binds, 
in a calcium-dependent a d lectin fashion, to the recombinant 
form of the gp160 envelope glycoprotein of H IV- 1 and inhibits 
the binding of the gpl60 to the CD4 receptor on CEM 13 cells 
[24]. It has been suggested that conglutinin plays a cross-linking 
role between the iC3b-coated microorganisms and comple- 
ment/collectin receptor [11]. In the present study, the behaviour 
of the recombinant BK-neck-CRD fragment of conglutinin on 
size-exclusion chromatography, and its binding to the TSK- 
GluNac affinity column, indicated that it is a homotrimer con- 
taining three CRD domains which are functionally intact and 
bind in a multivalent fashion to LPS from Gram-negative bac- 
teria and to C3b. The trimerisation of CRDs, by the neck 
region sequences forming an ~-helical bundle, is an important 
structural feature in determining the multivalency of binding 
shown by the collectins. 
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